BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22638872)

  • 21. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
    Britz H; Hanke N; Taub ME; Wang T; Prasad B; Fernandez É; Stopfer P; Nock V; Lehr T
    Pharm Res; 2020 Nov; 37(12):250. PubMed ID: 33237382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.
    Kimoto E; Li R; Scialis RJ; Lai Y; Varma MV
    Mol Pharm; 2015 Nov; 12(11):3943-52. PubMed ID: 26378985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.
    Mitra P; Kasliwala R; Iboki L; Madari S; Williams Z; Takahashi R; Taub ME
    Pharm Res; 2023 Dec; 40(12):3025-3042. PubMed ID: 37821766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.
    Nakagomi-Hagihara R; Nakai D; Tokui T; Abe T; Ikeda T
    Xenobiotica; 2007 May; 37(5):474-86. PubMed ID: 17523051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.
    Jamei M; Bajot F; Neuhoff S; Barter Z; Yang J; Rostami-Hodjegan A; Rowland-Yeo K
    Clin Pharmacokinet; 2014 Jan; 53(1):73-87. PubMed ID: 23881596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-Cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk.
    Ito K; Sjöstedt N; Malinen MM; Guo C; Brouwer KLR
    J Pharmacol Exp Ther; 2020 May; 373(2):261-268. PubMed ID: 32127372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.
    Yang Y; Li P; Zhang Z; Wang Z; Liu L; Liu X
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
    Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prediction of the pharmacokinetic drug-drug interaction of pravastatin and pitavastatin with cyclosporine by a digital liver model based on metabolism and transporter].
    Yin XF; Lin ZQ; Yang J
    Yao Xue Xue Bao; 2011 Sep; 46(9):1108-16. PubMed ID: 22121784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
    Varma MV; Lin J; Bi YA; Rotter CJ; Fahmi OA; Lam JL; El-Kattan AF; Goosen TC; Lai Y
    Drug Metab Dispos; 2013 May; 41(5):966-74. PubMed ID: 23393219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
    Mitra P; Weinheimer S; Michalewicz M; Taub ME
    Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):585-611. PubMed ID: 19936896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.
    Bosgra S; van de Steeg E; Vlaming ML; Verhoeckx KC; Huisman MT; Verwei M; Wortelboer HM
    Eur J Pharm Sci; 2014 Dec; 65():156-66. PubMed ID: 25261337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
    Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
    Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes.
    Kimoto E; Yoshida K; Balogh LM; Bi YA; Maeda K; El-Kattan A; Sugiyama Y; Lai Y
    Mol Pharm; 2012 Dec; 9(12):3535-42. PubMed ID: 23082789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.